Relationship of Sclerostin with PTH and Erythropoietin in-patient with CKD on dialysis in AL-Najaf Province.

Chronic kidney disease (CKD) is a condition that correlated with biochemical and clinical abnormalities due disturbances endocrine, which affects the function of the kidneys. Sclerostin, erythropoietin, and PTH have been shown to be associated with many complications related in patients with CKD. The study involved 21 male patients with (CKD) mean age (45.21?2.8 years) comprising nine no dialysis CKD, twelve patients with dialysis (end stage of CKD), who were attending kidney disease Center of Al-Sadder Teaching Hospital at Al-Najaf province. The exclusion criteria include blood transfusion in the last one-month and dialysis less than three months.Nine healthy volunteer male mean age (44.1?3.7 years) as control group. Estimated biomarkers sclerostin, PTH, and Epo, in addition to the age, body max index (BMI), red blood corpuscle (RBC), heamoglobin (Hb), ferritin, calcium, phosphor levels for all subject. Lower level of RBC, Hb, and calcium, while higher level of phosphor and ferritin in patient comparison with control group. Significant difference (P<0.05) between no-dialysis and dialysis groups in these parameters. Sclerostin and PTH levels was higher significantly but Epo levels lower significantly in CKD patients than controls (P<0.05), and highest in those with dialysis more than no- dialysis.Duration of dialysis showed a significant positive correlation with age (R? = 0.921), BMI (R? = 0.940), Phosphor (R? = 0.907), and PTH (R? = 0.874). While it was observed a significant negative correlation with Sclerostin (R? = 0.740), Calcium (R? = 0.863), and erythropoietin (R? = 0.714). A significant negative (P<0.01) correlation between Sclerostin serum levels after adjustment dialysis duration and PTH (r= ?0.92), while it`s a significant positively correlated with Erythropoietin (r=0.7) In conclusion, there is a relationship between sclerostin with each of Epo and PTH level, which affected with duration of dialysis in CKD patients.